Top

Published in:

01-02-2016 | Original Article

Circulating CD105 shows significant impact in patients of oral cancer and promotes malignancy of cancer cells via CCL20

Authors: Chang-Han Chen, Hui-Ching Chuang, Yu-Tsai Lin, Fu-Min Fang, Chao-Cheng Huang, Ching-Mei Chen, Hui Lu, Chih-Yen Chien

Published in: Tumor Biology | Issue 2/2016

Abstract

CD105 is rich in endothelium cells and is involved in angiogenesis. Higher microvascular density of tumor is also related to the prognosis in a variety of cancers. In this present study, patients with positive N classification, advanced T classification, advanced TNM stage, extracapsular spread of lymph nodes (ECS), and perineural invasion had significantly higher levels of peripheral vein (pCD105) and venous return from tumor (tCD105) in 71 patients with OSCC compared to 13 healthy volunteers. Those with higher pCD105 or tCD105 levels had significantly poorer 5-year disease-specific survival rate (DDS) and overall survival rate (OS). The tCD105 and pCD105 levels and ECS were the independent prognostic factors by the multivariate analysis according to the Cox regression model in 5-year DDS and OS rate. SAS and SCC4 cells treated with CD105 showed the increase in migration, invasion, and proliferation in vitro and in vivo. Furthermore, CCL20 expression participated in CD105-elicited cell motility in oral cancer cells. In conclusion, higher level of circulating CD105 is related to adverse pathological features among patients with OSCC. It is also a useful marker for evaluating the prognosis and targeting therapeutics of OSCC.

Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CH, et al. Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol. 2009;45(9):798–802. doi:10.1016/j.oraloncology.2008.12.006.CrossRefPubMed

Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res. 1997;3(7):1031–44.PubMed

Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14(7):1931–7. doi:10.1158/1078-0432.CCR-07-4478.CrossRefPubMed

Bobik A. Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol. 2006;26(8):1712–20. doi:10.1161/01.ATV.0000225287.20034.2c.CrossRefPubMed

Chuang HC, Su CY, Huang HY, Chien CY, Chen CM, Huang CC. High expression of CD105 as a prognostic predictor of early tongue cancer. Laryngoscope. 2006;116(7):1175–9. doi:10.1097/01.mlg.0000224338.56902.28.CrossRefPubMed

Martone T, Rosso P, Albera R, Migliaretti G, Fraire F, Pignataro L, et al. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. Oral Oncol. 2005;41(2):147–55. doi:10.1016/j.oraloncology.2004.08.001.CrossRefPubMed

Marioni G, Marino F, Giacomelli L, Staffieri C, Mariuzzi ML, Violino E, et al. Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol. 2006;126(6):633–9. doi:10.1080/00016480500452558.CrossRefPubMed

Chien CY, Su CY, Hwang CF, Chuang HC, Hsiao YC, Wu SL, et al. Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx. Head Neck. 2006;28(5):441–6. doi:10.1002/hed.20364.CrossRefPubMed

Marioni G, Staffieri A, Manzato E, Ralli G, Lionello M, Giacomelli L, et al. A higher CD105-assessed microvessel density and worse prognosis in elderly patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2011;137(2):175–80. doi:10.1001/archoto.2010.244.CrossRefPubMed

10.

Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461–70. doi:10.1056/NEJMoa032260.CrossRefPubMed

11.

Chen CH, Chang AY, Li SH, Tsai HT, Shiu LY, Su LJ, et al. Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer. Mol Cancer. 2015;14:83. doi:10.1186/s12943-015-0348-7.CrossRefPubMedPubMedCentral

12.

Calvayrac O, Rodriguez-Calvo R, Alonso J, Orbe J, Martin-Ventura JL, Guadall A, et al. CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: role of NF-kappaB. Arterioscler Thromb Vasc Biol. 2011;31(11):2733–41. doi:10.1161/ATVBAHA.111.235721.CrossRefPubMed

13.

Hwang CF, Shiu LY, Su LJ, Yu-Fang Y, Wang WS, Huang SC, et al. Oncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis. PloS one. 2013;8(12):e84218. doi:10.1371/journal.pone.0084218.CrossRefPubMedPubMedCentral

14.

Chen CH, Shiu LY, Su LJ, Huang CY, Huang SC, Huang CC, et al. FLJ10540 is associated with tumor progression in nasopharyngeal carcinomas and contributes to nasopharyngeal cell proliferation, and metastasis via osteopontin/CD44 pathway. J Transl Med. 2012;10:93. doi:10.1186/1479-5876-10-93.CrossRefPubMedPubMedCentral

15.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.CrossRefPubMed

16.

Yang TY, Chiang NY, Tseng WY, Pan HL, Peng YM, Shen JJ, et al. Expression and immunoaffinity purification of recombinant soluble human GPR56 protein for the analysis of GPR56 receptor shedding by ELISA. Protein Expr Purif. 2015;109:85–92. doi:10.1016/j.pep.2014.11.013.CrossRefPubMed

17.

Chen CH, Chuang HC, Huang CC, Fang FM, Huang HY, Tsai HT, et al. Overexpression of Rap-1A indicates a poor prognosis for oral cavity squamous cell carcinoma and promotes tumor cell invasion via Aurora-A modulation. Am J Pathol. 2013;182(2):516–28. doi:10.1016/j.ajpath.2012.10.023.CrossRefPubMed

18.

Chien CY, Tsai HT, Su LJ, Chuang HC, Shiu LY, Huang CC, et al. Aurora-A signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior. Oncotarget. 2014;5(8):2243–62.CrossRefPubMedPubMedCentral

19.

Hong DY, Lee BJ, Lee JC, Choi JS, Wang SG, Ro JH. Expression of VEGF, HGF, IL-6, IL-8, MMP-9, Telomerase in Peripheral Blood of Patients with Head and Neck Squamous Cell Carcinoma. Clin Exp Otorhinolaryngol. 2009;2(4):186–92. doi:10.3342/ceo.2009.2.4.186.CrossRefPubMedPubMedCentral

20.

Druzgal CH, Chen Z, Yeh NT, Thomas GR, Ondrey FG, Duffey DC, et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2005;27(9):771–84. doi:10.1002/hed.20246.CrossRefPubMed

21.

Teknos TN, Cox C, Yoo S, Chepeha DB, Wolf GT, Bradford CR, et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck. 2002;24(11):1004–11. doi:10.1002/hed.10163.CrossRefPubMed

22.

Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003;17(9):984–92. doi:10.1096/fj.02-0634rev.CrossRefPubMed

23.

Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, et al. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer. 2003;88(9):1424–31. doi:10.1038/sj.bjc.6600874.CrossRefPubMedPubMedCentral

24.

Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer J Int du Cancer. 2000;89(2):122–6.CrossRef

25.

Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res. 2008;14(11):3362–6. doi:10.1158/1078-0432.CCR-07-4707.CrossRefPubMed

26.

Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J. 2004;23(20):4018–28. doi:10.1038/sj.emboj.7600386.CrossRefPubMedPubMedCentral

27.

Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res. 2011;31(6):2283–90.PubMed

28.

Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, et al. Defective angiogenesis in mice lacking endoglin. Science. 1999;284(5419):1534–7.CrossRefPubMed

29.

Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res. 1995;1(12):1623–34.PubMed

30.

Paauwe M, ten Dijke P, Hawinkels LJ. Endoglin for tumor imaging and targeted cancer therapy. Expert Opin Ther Targets. 2013;17(4):421–35. doi:10.1517/14728222.2013.758716.CrossRefPubMed

31.

Nolan-Stevaux O, Zhong W, Culp S, Shaffer K, Hoover J, Wickramasinghe D, et al. Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PloS one. 2012;7(12):e50920. doi:10.1371/journal.pone.0050920.CrossRefPubMedPubMedCentral

32.

Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, et al. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res. 2012;18(17):4820–9. doi:10.1158/1078-0432.CCR-12-0098.CrossRefPubMedPubMedCentral

33.

Jonker L. TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as anti-angiogenic targets. Microcirculation. 2013;Accepted manuscript online. doi:10.1111/micc.12099.

34.

Choi KS, Bae MK, Jeong JW, Moon HE, Kim KW. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol. 2003;36(1):120–7.PubMed

35.

Tian F, Zhou AX, Smits AM, Larsson E, Goumans MJ, Heldin CH, et al. Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling in vivo and in vitro. Biochem Biophys Res Commun. 2010;392(3):283–8. doi:10.1016/j.bbrc.2009.12.170.CrossRefPubMed

36.

Sanz-Rodriguez F, Fernandez LA, Zarrabeitia R, Perez-Molino A, Ramirez JR, Coto E, et al. Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia: deficient endoglin up-regulation in activated monocytes. Clin Chem. 2004;50(11):2003–11. doi:10.1373/clinchem.2004.035287.CrossRefPubMed

37.

Torsney E, Charlton R, Parums D, Collis M, Arthur HM. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res. 2002;51(9):464–70.CrossRefPubMed

38.

Scharpfenecker M, Floot B, Russell NS, Stewart FA. The TGF-beta co-receptor endoglin regulates macrophage infiltration and cytokine production in the irradiated mouse kidney. Radiother Oncol. 2012;105(3):313–20. doi:10.1016/j.radonc.2012.08.021.CrossRefPubMed

39.

Wolff HA, Rolke D, Rave-Frank M, Schirmer M, Eicheler W, Doerfler A, et al. Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines. Radiat Environ Biophys. 2011;50(1):145–54. doi:10.1007/s00411-010-0341-x.CrossRefPubMed

40.

Ding X, Wang K, Wang H, Zhang G, Liu Y, Yang Q, et al. High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. J Gastrointest Surg. 2012;16(4):828–36. doi:10.1007/s11605-011-1775-4.CrossRefPubMed

Title: Circulating CD105 shows significant impact in patients of oral cancer and promotes malignancy of cancer cells via CCL20
Authors: Chang-Han Chen
Hui-Ching Chuang
Yu-Tsai Lin
Fu-Min Fang
Chao-Cheng Huang
Ching-Mei Chen
Hui Lu
Chih-Yen Chien
Publication date: 01-02-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3991-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

∆Np73beta induces caveolin-1 in human non-small cell lung cancer cell line H1299

Erratum to: Abstract supplement The 42nd Congress of the International Society of Oncology and Biomarkers “ONOCOLOGY IN THE BIOMARKER ERA: Biology – Diagnostics – Therapy” ISOBM 2015

Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib

The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis

The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker

Pretreatment anemia and survival in nasopharyngeal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer